Login / Signup

Ocrelizumab alters the circulating metabolome in people with relapsing-remitting multiple sclerosis.

Fatemeh SiavoshiDimitrios Christos LadakisAshley MullerBardia NourbakhshPavan Bhargava
Published in: Annals of clinical and translational neurology (2024)
In this longitudinal observational study, using a global untargeted metabolomics approach, we showed significant alteration in circulating metabolome in RRMS patients undergoing ocrelizumab treatment. In particular, we observed a significant reduction in metabolites involved in the lysophospholipid pathway, which was associated with patients' improvement.
Keyphrases